バイオマーカー市場：製品・サービス（消耗品、サービス、ソフトウェア）、タイプ（安全性、有効性、検証）、疾患（癌、感染症、神経）、用途（診断、創薬、個別化医療）、地域別-2028年までの世界予測

Biomarkers Market by Product & Service (Consumable, Service, Software), Type (Safety, Efficacy, Validation), Disease (Cancer, Infectious, Neurological), Application (Diagnostics, Drug Discovery, Personalized Medicine), Region - Global Forecast to 2028

バイオマーカーの世界市場は、2023年の591億米ドルから2028年には1040億米ドルに達すると予測され、CARGは12.0%となる。バイオマーカー市場の成長の要因は、主に診断の重要性の高まり、癌や心臓疾患の有病率の増... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年2月23日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	246	296	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

バイオマーカーの世界市場は、2023年の591億米ドルから2028年には1040億米ドルに達すると予測され、CARGは12.0%となる。バイオマーカー市場の成長の要因は、主に診断の重要性の高まり、癌や心臓疾患の有病率の増加、バイオマーカー研究のための資金や助成金の増加、継続的な製品革新、バイオマーカーの進歩などの要因である。しかし、バイオマーカーの検証に時間がかかる、コストが高い、アッセイの開発が難しいなどの要因が、市場の成長を妨げています。
"予測期間中、バイオマーカー市場の最大の成長セグメントを占めたのは、疾患適応症別セグメントのうち、がんセグメントでした。"
疾患適応症に基づき、バイオマーカー市場は感染症、神経疾患、免疫疾患、がん、心血管疾患、その他の疾患適応症に分けられます。予測期間（2023-2028年）において、バイオマーカー市場では、がん分野が最も急速に成長すると予想されます。今後、がんバイオマーカーは、大手メーカーによるがんバイオマーカー関連の強力な製品パイプラインによって、さらに活性化されると予想されます。同分野の高成長の要因としては、がんバイオマーカーによる早期管理、早期発見などが挙げられます。
"2022年、アプリケーション別では、診断分野がバイオマーカー市場で最大のシェアを占めた。"
用途別に見ると、バイオマーカー市場は、創薬・開発、個別化医療、診断、疾患リスク評価、その他の用途に分けられます。2022年、バイオマーカー市場の用途別セグメントでは、診断分野が最大のシェアを占めています。同分野の成長要因としては、慢性疾患の流行に伴い同分野が拡大し、標的治療や診断の需要が高まることが挙げられます。また、バイオマーカーの用途が拡大していることも、バイオマーカー市場の診断分野の成長を後押ししています。
"2022年、北米がバイオマーカー市場で最大のシェアを占める"
2022年、北米が最大のシェアを占める。同地域の成長の要因としては、同地域の慢性疾患に苦しむ人口の増加、個別化医療におけるバイオマーカーの利用の増加、同地域の既存製薬会社と主要プレーヤーが採用する様々な有機・無機成長戦略、バイオマーカーの用途拡大と進歩が挙げられます。さらに、この地域の政府は、希少な神経変性疾患のバイオマーカーの特定に注力しており、これが市場に新たな機会をもたらすと考えられます。

予備選の内訳

本調査には、部品サプライヤーからティア1企業、OEMに至るまで、様々な業界専門家による洞察が含まれています。プライマリーの内訳は以下の通りです：

- 回答者別：供給側70％、需要側30％。
- 役職別-CXOおよびディレクター-30％、エグゼクティブ-25％、マネジャー-45
- 地域別：北米40％、欧州25％、APAC20％、RoW15％。

バイオマーカー市場は、F. Hoffmann-La Roche Ltd.（スイス）、Thermo Fisher Scientific Inc.(スイス）、Thermo Fisher Scientific Inc.（米国）、Abbott Laboratories（米国）、QIAGEN N.V.（オランダ）、PerkinElmer, Inc.（米国）、Merck KGaA（ドイツ）、Bio-Rad Laboratories, Inc（米国）、ENZO BIOCHEM, INC（米国）、Charles River Laboratories International, Inc （米国）、Eurofins Scientific S.E （ルクセンブルク）、Meso Scale Diagnostics, LLC.(米国）、Stressmarq Biosciences（カナダ）、DiaMetra Srl（イタリア）、Signosis, Inc.（米国）、Agilent Technologies, Inc.（米国）、Johnson & Johnson（米国）、bioMérieux SA（フランス）、EKF Diagnostics Holdings, Plc（英国）、MicroConstants, Inc.（米国）、NorthEast BioAnalytical Laboratories LLC.(米国）、JSR Life Sciences, LLC（米国）、BioAgilytix Labs（米国）、Celerion（米国）、Singulex, Inc.（米国）、Cisbio Bioassays（フランス）です。

研究対象です：

本レポートでは、バイオマーカー市場を地域（アジア太平洋地域、欧州、北米、その他の地域）、製品（消耗品サービス、ソフトウェア）、タイプ（安全性バイオマーカー、有効性バイオマーカー［予測バイオマーカー、代替バイオマーカー、薬力学バイオマーカー、予後バイオマーカー］、検証バイオマーカー）、アプリケーション（診断、創薬・開発）で分類し、その結果を掲載しています。
個別化医療、疾患リスク評価、その他の用途）、疾患適応症（がん、感染症、免疫疾患、神経疾患、心血管疾患、その他の疾患適応症）。また、バイオマーカー市場における市場促進要因、阻害要因、機会、課題、動向について包括的にレビューしています。

レポート購入の主なメリット

本レポートは、市場全体とサブセグメントの収益数字の最も近い近似値に関する情報を提供し、この市場のリーダー/新規参入者に役立ちます。本レポートは、関係者が競争環境を理解し、より多くの洞察を得ることで、事業の位置づけを高め、適切な市場参入戦略を計画するのに役立ちます。また、本レポートは、関係者がバイオマーカー市場の鼓動を理解し、主要な市場促進要因、阻害要因、課題、および機会に関する情報を提供するのに役立ちます。

ページTOPに戻る

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.2.1 INCLUSIONS & EXCLUSIONS 34
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 BIOMARKERS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED 35
1.4 CURRENCY 35
1.5 LIMITATIONS 35
1.6 STAKEHOLDERS 36
1.7 SUMMARY OF CHANGES 36
1.7.1 RECESSION IMPACT 36
2 RESEARCH METHODOLOGY 37
2.1 RESEARCH APPROACH 37
FIGURE 2 BIOMARKERS MARKET: RESEARCH DESIGN 37
2.1.1 SECONDARY RESEARCH 37
2.1.1.1 Secondary sources 39
2.1.2 PRIMARY RESEARCH 39
2.1.2.1 Primary sources 40
2.1.2.2 Primary sources 41
2.1.2.3 Breakdown of primaries 41
FIGURE 3 BIOMARKERS MARKET: BREAKDOWN OF PRIMARIES 41
2.2 MARKET SIZE ESTIMATION 42
FIGURE 4 BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 42
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022 43
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF ALL BIOMARKER PRODUCTS IN THE MARKET 43
FIGURE 7 KEY INDUSTRY INSIGHTS 45
FIGURE 8 BIOMARKERS MARKET: CAGR PROJECTIONS, 2023–2028 46
FIGURE 9 BIOMARKERS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 46
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 47
FIGURE 10 DATA TRIANGULATION METHODOLOGY 48
2.4 RESEARCH LIMITATIONS 48
2.5 RESEARCH ASSUMPTIONS 49
2.6 RISK ANALYSIS 49
2.7 RECESSION IMPACT 49
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 49
3 EXECUTIVE SUMMARY 51
FIGURE 11 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 51
FIGURE 12 BIOMARKERS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 52
FIGURE 13 BIOMARKERS MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD MILLION) 52
FIGURE 14 BIOMARKERS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 53
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF BIOMARKERS MARKET 54
4 PREMIUM INSIGHTS 55
4.1 BIOMARKERS MARKET OVERVIEW 55
FIGURE 16 GROWING IMPORTANCE OF COMPANION DIAGNOSTICS EXPECTED TO DRIVE BIOMARKERS MARKET 55
4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE AND BY COUNTRY (2022) 56
FIGURE 17 CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022 56
4.3 BIOMARKERS MARKET, BY REGION, 2022 57
FIGURE 18 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 57
5 MARKET OVERVIEW 58
5.1 MARKET DYNAMICS 58
FIGURE 19 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 58
5.1.1 MARKET DRIVERS 59
5.1.1.1 Growing importance of companion diagnostics 59
5.1.1.2 Increase in global prevalence of cancer 60
TABLE 2 NUMBER OF NEW CANCER CASES, BY TYPE, 2020–2040 60
TABLE 3 CANCER INCIDENCE, BY REGION (2040) 61
5.1.1.3 Increase in funds and grants for biomarker research 61
5.1.1.4 Continuous product innovations 62
TABLE 4 PRODUCT LAUNCHES, 2020−2022 62
5.1.2 RESTRAINTS 63
5.1.2.1 High capital investments and lengthy timelines for biomarker development 63
TABLE 5 TIME FRAME FOR BIOMARKER DEVELOPMENT 63
5.1.3 OPPORTUNITIES 64
5.1.3.1 Personalized medicine 64
5.1.3.2 Emerging economies 65
5.1.4 CHALLENGES 65
5.1.4.1 Challenges associated with biomarker validation 65
5.1.4.2 Technical issues related to sample collection and storage 65

5.2 REGULATORY ASSESSMENT 66
5.2.1 INTRODUCTION 66
5.2.2 BIOMARKER QUALIFICATION IN US 66
5.2.3 BIOMARKER QUALIFICATION IN EUROPE 66
5.3 VALUE CHAIN ANALYSIS 67
FIGURE 20 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS 67
5.4 TECHNOLOGICAL ANALYSIS 67
5.4.1 IMMUNOASSAYS 68
5.4.1.1 Immunohistochemistry (IHC) 68
5.4.1.2 Flow cytometry 68
5.4.1.3 Flow cytometry ELISA 68
5.4.2 NEXT-GENERATION SEQUENCING (NGS) 68
5.4.3 POLYMERASE CHAIN REACTION (PCR) 69
5.4.4 IN SITU HYBRIDIZATION 69
5.4.5 MICROARRAYS 69
5.4.6 MASS SPECTROMETRY 70
5.5 PRICING ANALYSIS 70
TABLE 6 SELLING PRICE OF BIOMARKERS BY TOP PLAYERS 70
5.6 PATENT ANALYSIS 72
FIGURE 21 PATENT APPLICATIONS FOR BIOMARKERS MARKET, JANUARY 2012–DECEMBER 2022 72
5.7 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 73
FIGURE 22 BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS 74
5.7.1 KEY INFLUENCERS 74
5.8 ECOSYSTEM ANALYSIS 75
TABLE 7 BIOMARKERS MARKET: SUPPLY CHAIN ECOSYSTEM 75
5.9 KEY CONFERENCES AND EVENTS, 2023–2024 76
TABLE 8 BIOMARKERS MARKET: LIST OF CONFERENCES AND EVENTS 76
5.10 PORTER’S FIVE FORCES ANALYSIS 78
5.10.1 IMPACT OF PORTER’S FIVE FORCES ON BIOMARKERS MARKET 78
5.10.2 INTENSITY OF COMPETITIVE RIVALRY 78
5.10.3 BARGAINING POWER OF SUPPLIERS 78
5.10.4 BARGAINING POWER OF BUYERS 79
5.10.5 THREAT OF SUBSTITUTES 79
5.10.6 THREAT OF NEW ENTRANTS 79
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 79
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 79
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKERS 79
5.11.2 BIOMARKERS MARKET: BUYING CRITERIA 80
FIGURE 24 KEY BUYING CRITERIA FOR END USERS 80
5.12 ECOSYSTEM ANALYSIS OF BIOMARKERS MARKET 80
FIGURE 25 BIOMARKERS MARKET: ECOSYSTEM ANALYSIS 80
5.12.1 ROLE IN ECOSYSTEM 81
5.13 REVENUE SHIFT FOR BIOMARKERS MARKET 81
FIGURE 26 BIOMARKERS MARKET: REVENUE SHIFT 81
6 BIOMARKERS MARKET, BY PRODUCT & SERVICE 82
6.1 INTRODUCTION 83
TABLE 9 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 83
6.2 CONSUMABLES 83
6.2.1 NEED FOR HIGH-FREQUENCY PURCHASE OF CONSUMABLES TO DRIVE MARKET GROWTH 83
TABLE 10 BIOMARKER CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 84
TABLE 11 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 12 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 13 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 14 ROW: BIOMARKER CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 85
6.3 SERVICES 85
6.3.1 GRADUAL SHIFT FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING OF SERVICES TO SUPPORT MARKET GROWTH 85
TABLE 15 BIOMARKER SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 16 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 17 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 18 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 19 ROW: BIOMARKER SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 87
6.4 SOFTWARE 87
6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO SUPPORT MARKET GROWTH 87
TABLE 20 BIOMARKER SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 21 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 22 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 23 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 24 ROW: BIOMARKER SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 89

7 BIOMARKERS MARKET, BY TYPE 90
7.1 INTRODUCTION 91
TABLE 25 BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 91
7.2 EFFICACY BIOMARKERS 91
TABLE 26 EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 92
TABLE 27 EFFICACY BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 92
TABLE 28 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 29 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 30 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 31 ROW: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 93
7.2.1 PREDICTIVE BIOMARKERS 94
7.2.1.1 Wide applications of predictive biomarkers in personalized medicine and companion diagnostics to drive market 94
TABLE 32 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 94
TABLE 33 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 34 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 35 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 36 ROW: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 95
7.2.2 SURROGATE BIOMARKERS 96
7.2.2.1 Use of surrogate biomarkers helps accelerate drug development and shorten timelines for regulatory approval 96
TABLE 37 SURROGATE BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 38 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 39 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 40 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 41 ROW: SURROGATE BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 97
7.2.3 PHARMACODYNAMIC BIOMARKERS 98
7.2.3.1 Increasing utilization of pharmacodynamic biomarkers in selection and optimization of drug doses to boost market 98
TABLE 42 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 43 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 44 EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 45 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 46 ROW: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 99
7.2.4 PROGNOSTIC BIOMARKERS 100
7.2.4.1 Prognostic biomarkers help predict recurrence of diseases 100
TABLE 47 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 48 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 49 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 50 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 51 ROW: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 101
7.3 SAFETY BIOMARKERS 102
7.3.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT TO FUEL MARKET GROWTH 102
TABLE 52 SAFETY BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 53 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 54 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 55 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 56 ROW: SAFETY BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
7.4 VALIDATION BIOMARKERS 104
7.4.1 VALIDATION BIOMARKERS ENABLE EVALUATION OF DIAGNOSTIC SYSTEMS 104
TABLE 57 VALIDATION BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 58 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 59 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 60 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 61 ROW: VALIDATION BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 106
8 BIOMARKERS MARKET, BY DISEASE INDICATION 107
8.1 INTRODUCTION 108
TABLE 62 BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 108

8.2 CANCER 108
8.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET 108
TABLE 63 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER 109
TABLE 64 BIOMARKERS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 65 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 66 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 67 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 68 ROW: BIOMARKERS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 111
8.3 INFECTIOUS DISEASES 111
8.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE DEMAND FOR BIOMARKERS 111
TABLE 69 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 112
TABLE 70 NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 71 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 72 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 73 ROW: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 113
8.4 IMMUNOLOGICAL DISORDERS 113
8.4.1 INCREASING ADOPTION OF BIOMARKERS FOR VARIOUS IMMUNOLOGICAL DISORDERS TO DRIVE MARKET 113
TABLE 74 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS 114
TABLE 75 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 76 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 77 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 78 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 79 ROW: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 116
8.5 NEUROLOGICAL DISORDERS 116
8.5.1 IMMUNOASSAYS WIDELY USED IN DIAGNOSIS OF NEUROLOGICAL DISORDERS 116
TABLE 80 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 81 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 82 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 83 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 84 ROW: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 118
8.6 CARDIOVASCULAR DISORDERS 118
8.6.1 GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS 118
TABLE 85 BIOMARKERS FOR CARDIOVASCULAR DISORDERS 118
TABLE 86 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2021–2028 (USD MILLION) 119
TABLE 87 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 88 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 89 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 90 ROW: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2021–2028 (USD MILLION) 120
8.7 OTHER DISEASE INDICATIONS 120
TABLE 91 BIOMARKERS FOR RENAL DISORDERS 121
TABLE 92 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 121
TABLE 93 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 94 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 95 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 96 ROW: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 123
9 BIOMARKERS MARKET, BY APPLICATION 124
9.1 INTRODUCTION 125
TABLE 97 BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 125
9.2 DIAGNOSTICS 125
9.2.1 INCREASING USE OF BIOMARKERS FOR DIAGNOSIS OF VARIOUS DISEASES TO DRIVE GROWTH 125
TABLE 98 BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 99 NORTH AMERICA: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 100 EUROPE: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 101 ASIA PACIFIC: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 102 ROW: BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 127
9.3 DRUG DISCOVERY & DEVELOPMENT 127
9.3.1 BIOMARKERS PLAY KEY ROLE AS BIOLOGICAL INDICATORS IN DEVELOPMENT OF NEW DRUGS 127
TABLE 103 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 128
TABLE 104 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 105 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 106 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 107 ROW: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 129
9.4 PERSONALIZED MEDICINE 130
9.4.1 INCREASING APPLICATIONS OF BIOMARKERS IN PERSONALIZED MEDICINE TO DRIVE MARKET 130
TABLE 108 SELECTED PERSONALIZED MEDICINE DRUGS AND RELEVANT BIOMARKERS 130
TABLE 109 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 110 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 111 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 112 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 113 ROW: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 132
9.5 DISEASE RISK ASSESSMENT 132
9.5.1 BIOMARKERS WIDELY USED FOR TOXICITY CHARACTERIZATION IN DISEASE DIAGNOSIS AND DRUG DEVELOPMENT PROCESSES 132
TABLE 114 BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 115 NORTH AMERICA: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 116 EUROPE: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 117 ASIA PACIFIC: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 118 ROW: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2021–2028 (USD MILLION) 134
9.6 OTHER APPLICATIONS 134
TABLE 119 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 120 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 121 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 122 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 123 ROW: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 136
10 BIOMARKERS MARKET, BY REGION 137
10.1 INTRODUCTION 138
TABLE 124 BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 138
10.2 NORTH AMERICA 139
FIGURE 27 NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT 139
TABLE 125 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 126 NORTH AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 140
TABLE 127 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 128 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 129 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141
TABLE 130 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 142
10.2.1 US 142
10.2.1.1 US expected to dominate biomarkers market in North America during forecast period 142
TABLE 131 US: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 143
TABLE 132 US: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 133 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 134 US: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144
TABLE 135 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 144
10.2.2 CANADA 144
10.2.2.1 Increasing incidence of cancer to drive growth of biomarker research 144
TABLE 136 CANADA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145
TABLE 137 CANADA: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 138 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 139 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 140 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 146
10.2.3 NORTH AMERICA: RECESSION IMPACT 147

10.3 EUROPE 147
TABLE 141 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 142 EUROPE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 148
TABLE 143 EUROPE: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 144 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 145 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 149
TABLE 146 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 150
10.3.1 GERMANY 150
10.3.1.1 Increase in government funding for biomarker research to drive market growth 150
TABLE 147 GERMANY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 150
TABLE 148 GERMANY: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 149 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 150 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 151
TABLE 151 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 152
10.3.2 UK 152
10.3.2.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers 152
TABLE 152 UK: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 152
TABLE 153 UK: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 154 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 155 UK: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 153
TABLE 156 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 154
10.3.3 FRANCE 154
10.3.3.1 Increasing government investments in genomics and proteomics research to drive market growth 154
TABLE 157 FRANCE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 154
TABLE 158 FRANCE: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 159 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 155
TABLE 160 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155
TABLE 161 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 156
10.3.4 ITALY 156
10.3.4.1 Increasing life science R&D funding to drive market growth 156
TABLE 162 ITALY: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 156
TABLE 163 ITALY: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 164 ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 165 ITALY: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157
TABLE 166 ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 158
10.3.5 SPAIN 158
10.3.5.1 Growing focus on cancer biomarkers to propel market growth 158
TABLE 167 SPAIN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 158
TABLE 168 SPAIN: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 169 SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 170 SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 159
TABLE 171 SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 160
10.3.6 REST OF EUROPE 160
TABLE 172 REST OF EUROPE: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 160
TABLE 173 REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 174 REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 175 REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 161
TABLE 176 REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 162
10.3.7 EUROPE: RECESSION IMPACT 162
10.4 ASIA PACIFIC 163
TABLE 177 ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 178 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 163
TABLE 179 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 180 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 181 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 164
TABLE 182 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 165
10.4.1 CHINA 165
10.4.1.1 Increasing burden of diseases and growing focus on development of novel drugs to drive demand for biomarkers 165
TABLE 183 CHINA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 165
TABLE 184 CHINA: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 185 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 186 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 166
TABLE 187 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 167
10.4.2 JAPAN 167
10.4.2.1 Strategic collaborations with leading pharmaceutical companies to drive market 167
TABLE 188 JAPAN: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 168
TABLE 189 JAPAN: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 190 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 191 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 169
TABLE 192 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 169
10.4.3 INDIA 169
10.4.3.1 Growing prevalence of target diseases expected to support biomarkers market 169
TABLE 193 INDIA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 170
TABLE 194 INDIA: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 195 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 170
TABLE 196 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 171
TABLE 197 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 171
10.4.4 REST OF ASIA PACIFIC 171
TABLE 198 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 172
TABLE 199 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 200 REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 201 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 173
TABLE 202 REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 173
10.4.5 ASIA PACIFIC: RECESSION IMPACT 173
10.5 REST OF THE WORLD 174
TABLE 203 ROW: BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 174
TABLE 204 ROW: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 174
TABLE 205 ROW: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 206 ROW: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 207 ROW: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 175
TABLE 208 ROW: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 176
10.5.1 LATIN AMERICA 176
10.5.1.1 Research funding and rising awareness of advanced sequencing technologies to drive market 176
TABLE 209 LATIN AMERICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 177
TABLE 210 LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 211 LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 212 LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 178
TABLE 213 LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 178
10.5.2 LATIN AMERICA: RECESSION IMPACT 178
10.5.3 MIDDLE EAST & AFRICA 179
10.5.3.1 Increasing focus on proteomics and genomics research to support market growth 179
TABLE 214 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 179
TABLE 215 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 216 MIDDLE EAST & AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2021–2028 (USD MILLION) 180
TABLE 217 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 180
TABLE 218 MIDDLE EAST & AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 181
10.5.4 MIDDLE EAST & AFRICA: RECESSION IMPACT 181
11 COMPETITIVE LANDSCAPE 182
11.1 INTRODUCTION 182
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 182
FIGURE 28 BIOMARKERS MARKET: STRATEGIES ADOPTED 183
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 183
FIGURE 29 REVENUE ANALYSIS OF KEY COMPANIES OVER LAST THREE YEARS (2019–2022) 184
11.4 MARKET SHARE ANALYSIS 184
FIGURE 30 BIOMARKERS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 185
TABLE 219 BIOMARKERS MARKET: DEGREE OF COMPETITION 185
11.5 COMPANY EVALUATION QUADRANT 186
FIGURE 31 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX, 2022 186
11.5.1 STARS 187
11.5.2 EMERGING LEADERS 187
11.5.3 PERVASIVE PLAYERS 187
11.5.4 PARTICIPANTS 187
11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 188
11.6.1 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES) 188
TABLE 220 BIOMARKERS MARKET: PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS 188
11.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 189
TABLE 221 BIOMARKERS MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 189
11.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES 190
FIGURE 32 BIOMARKERS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 190
11.7.1 PROGRESSIVE COMPANIES 191
11.7.2 STARTING BLOCKS 191
11.7.3 RESPONSIVE COMPANIES 191
11.7.4 DYNAMIC COMPANIES 191
11.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 191
TABLE 222 BIOMARKERS MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 191
TABLE 223 BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 192
11.9 COMPETITIVE SCENARIOS AND TRENDS 192
11.9.1 PRODUCT LAUNCHES 192
TABLE 224 BIOMARKERS MARKET: PRODUCT LAUNCHES, JANUARY 2020–DECEMBER 2022 193
11.9.2 DEALS 194
TABLE 225 BIOMARKERS MARKET: DEALS, JANUARY 2020–DECEMBER 2022 194
11.9.3 EXPANSIONS 195
TABLE 226 BIOMARKERS MARKET: EXPANSIONS, JANUARY 2020–DECEMBER 2022 195

ページTOPに戻る

Table of Contents

Summary

The global biomarkers market is expected to reach USD 104.0 billion in 2028 from USD 59.1 billion in 2023 at a CARG of 12.0%. Factors responsible for the growth in the biomarkers market are mainly factors such as the growing importance of diagnostics, increasing prevalence of cancer and cardiac problems, increasing funds & grants for biomarker research, continuous product innovations, and biomarker advancements. However, factors such as time-consuming process of biomarker validation, high cost, and difficulty in developing assays are hampering the growth of the market.
“During the forecast period, the cancer segment of by disease indications segment, accounted for the largest growing segment of the biomarkers market.”
Based on disease indication, the biomarkers market is divided into infectious diseases, neurological disorders, immunological disorders, cancer, cardiovascular disorders, and other disease indications. During the forecast period (2023-2028), the cancer segment is expected to be the fastest-growing segment in the biomarkers market. In the future, the cancer biomarkers are expected to be further boosted by a strong pipeline of products from major manufacturers related to cancer biomarkers. Factors responsible for the high growth of the segment includes early management and early detection by cancer biomarkers.
“In 2022, by application, the diagnostics segment accounted for the biggest share of the biomarkers market.”
Based on application, the biomarkers market is divided into drug discovery & development, personalized medicine, diagnostics, disease risk assessment, and other applications. In 2022, the diagnostics segment accounted for the largest share of the application segment in the biomarkers market. Factor responsible for the growth in this segment include, the segment will expand as chronic diseases will become more prevalent, and targeted treatment and diagnosis demand will increase. The growing applications of biomarkers is also driving the growth of the diagnostics segment of the biomarkers market.
“In 2022, North America accounted for the largest share of the biomarkers market.”
In 2022, North America accounted for the largest share of the market. Factors responsible for the growth of the region includes increasing population suffering from chronic diseases in the region, increasing use of biomarkers in personalized medicine, various organic & inorganic growth strategies adopted by key players with established pharmaceutical companies in this region, increasing applications and advancements in biomarkers. Additionally, the regional government is also focusing on identifying biomarkers for rare neurodegenerative diseases, which will create new opportunities for market.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

• By Respondent– Supply Side- 70%, Demand Side-30%
• By Designation— CXOs and Directors- 30%, Executives - 25%, Mangers - 45%
• By Region— North America - 40%, Europe - 25%, APAC – 20%, RoW- 15%

The biomarkers market is dominated by a few globally established players such as F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), ENZO BIOCHEM, INC. (US), Charles River Laboratories International, Inc. (US), Eurofins Scientific S.E. (Luxembourg), Meso Scale Diagnostics, LLC. (US), Stressmarq Biosciences (Canada), DiaMetra Srl (Italy), Signosis, Inc. (US), Agilent Technologies, Inc. (US), Johnson & Johnson (US), bioMérieux SA (France), EKF Diagnostics Holdings, Plc (UK), MicroConstants, Inc. (US), NorthEast BioAnalytical Laboratories LLC. (US), JSR Life Sciences, LLC (US), BioAgilytix Labs (US), Celerion (US), Singulex, Inc. (US), and Cisbio Bioassays (France).

Research Coverage:

The report segments the biomarkers market based on region (Asia Pacific, Europe, North America, and Rest of the World), product (consumables services, software), type (safety biomarkers, efficacy biomarkers [predictive biomarkers, surrogate biomarkers, pharmacodynamics biomarkers, prognostic biomarkers], and validation biomarkers, application (diagnostics, drug discovery & development
personalized medicine, disease risk assessment and other applications), and disease indications (cancer, infectious diseases, immunological disorders, neurological disorders, cardiovascular disorders, and other disease indications). The report also provides a comprehensive review of market drivers, restraints opportunities, challenges and trends in the biomarkers market.

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the biomarkers market and provides them with information on key market drivers, restraints, challenges, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（biomarkers market）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

バイオマーカー市場：製品・サービス（消耗品、サービス、ソフトウェア）、タイプ（安全性、有効性、検証）、疾患（癌、感染症、神経）、用途（診断、創薬、個別化医療）、地域別-2028年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（biomarkers market）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?